Recombinant Human ICAM-1/CD54 Protein

重组人ICAM-1/CD54蛋白 | 重组人类 ICAM-1/CD54 蛋白

CD54 antigen | CD54 | cell surface glycoprotein P3.58 | human rhinovirus receptor | ICAM1 | ICAM-1 | intercellular adhesion molecule 1 (CD54), human rhinovirus receptor | intercellular adhesion molecule 1 | Major group rhinovirus receptor | P3.58 | BB2

rp181245-10μg

10μg

无动物源

≥95%(SDS-PAGE)

Protein Function: Intercellular adhesion molecule-1 (ICAM-1, or CD54) is a 90 kDa member of the immunoglobulin (Ig) superfamily and is critical for the firm arrest and transmigration of leukocytes out of blood vessels and into tissues. ICAM-1 is constitutively present on endothelial cells, but its expression is increased by proinflammatory cytokines. The endothelial expression of ICAM-1 is increased in atherosclerotic and transplant-associated atherosclerotic tissue and animal models of atherosclerosis. Additionally, ICAM-1 has been implicated in the progression of autoimmune diseases. ICAM-1 is a ligand for LFA-1(integrin). When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 interaction and then transmigrate into tissues. Presence with heavy glycosylation and other structural characteristics, ICAM-1 possesses binding sites for some immune-associated ligands and serves as the binding site for entry of the major group of human Rhinovirus (HRV) into various cell types. ICAM-1 also becomes known for its affinity for Plasmodium falciparum-infected erythrocytes (PFIE), providing more of a role in infectious disease. Previous studies have shown that ICAM-1 is involved in inflammatory reactions and that a defect in ICAM-1 gene inhibits allergic contact hypersensitivity.

Measured by the ability of the immobilized protein to support the adhesion of 5 μg/mL PHA-stimulated human Jurkat T lymphocyte leukemia cell for 2h. The ED50 for this effect is 0.1892 μg/mL.

重组表达

50.6 kDa

C-His

62.6-88.8 kDa, under reducing conditions; 58.1-81.5 kDa, under non-reducing conditions

HEK293 Accession #: P05362 | HEK293

<1.0 EU/μg

人(Human)

1-480 aa

MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYEHHHHHHHH

Yes

Yes